NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Weight Loss & Metabolic/Tirzepatide

Tirzepatide

An approved dual GIP and GLP-1 receptor agonist peptide for type 2 diabetes and obesity, given by once-weekly injection.

Overview

Tirzepatide is a synthetic peptide that acts as an agonist at both the GIP and GLP-1 receptors, the first dual incretin agonist to reach approval (Mounjaro for type 2 diabetes and Zepbound for obesity). It is administered by once-weekly subcutaneous injection and has produced some of the largest mean weight losses seen in obesity pharmacotherapy trials.

Mechanism

Tirzepatide is engineered as a single peptide with activity at both receptors. The GIP component is believed to augment the GLP-1-mediated effects on appetite and insulin secretion, although the exact contribution of GIP agonism is still being defined. Net effects include glucose-dependent insulin release, reduced food intake, and improved insulin sensitivity.

Dosing

Approved use is once-weekly subcutaneous injection with dose titration over several weeks to the maintenance dose. Doses are label-defined, and use outside prescribing is not clinically validated.

  • Weekly subcutaneous dosing per the approved labels
  • Gradual titration reduces gastrointestinal intolerance
  • Research-context use outside approved indications is unsupported

Expected Effects

  • Large reductions in HbA1c in type 2 diabetes trials
  • Substantial dose-dependent weight loss in obesity trials
  • Improvements in lipids and blood pressure reported in trials

Side Effects & Tolerability

Gastrointestinal events, including nausea, diarrhea, vomiting, and constipation, are the most common adverse effects. Label warnings cover pancreatitis, gallbladder disease, and thyroid C-cell tumors observed in rodents. As a relatively new drug, long-term safety continues to be monitored.

Storage

Approved products are stored refrigerated before first use. Lyophilized research peptide should be stored cold and desiccated, protected from light, per the supplier certificate of analysis.

Related peptides

AdipotideInvestigational prohibitin-targeting pro-apoptotic peptide conjugate studied in obese mice and monkeys to reduce adipose vasculature; not tested in humans.Advanced Thermogenic Master AnalogsMarketing-style catalog label implying peptides that enhance thermogenesis; no defined compound exists under this name in the literature.AMPK & mTOR Balance AnalogsCatalog label implying peptides that modulate the AMPK/mTOR signaling balance; no specific compounds are characterized under this name.Amylin Analogs (Expanded)Class listing for synthetic analogs of the pancreatic hormone amylin; pramlintide is the approved reference agent, while novel long-acting analogs are investigational.Autophagy Enhancer Peptide AnalogsCatalog category for peptides claimed to enhance autophagy; not a recognized compound class in the literature.C-Peptide AnalogsSynthetic peptides related to the proinsulin connecting peptide, whose native form has been studied as an adjunct in type 1 diabetes; analogs are undocumented.